Sponsor:
Varian, a Siemens Healthineers Company
Code:
NCT06681233
Conditions
Head and Neck Cancers
Breast Cancer
Thoracic Cancers
Liver Cancer
Genito Urinary Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
Brief summary:
Conditions
Head and Neck Cancers
Breast Cancer
Thoracic Cancers
Liver Cancer
Genito Urinary Cancer
Study ID
NCT06681233
Start date
Feb 19, 2025
Status verified date
Mar, 2026
Completion date
Sep, 2026
Anticipated
Primary completion date
Aug, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
50 participants
Anticipated
Intervention Model
Single group
Primary purpose
Other
Arms
experimental: HyperSight Imaging Arm
Interventions
Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
Primary outcome measure
Central contacts
Locations
James Outpatient Center
Recruiting
Columbus, Ohio, United States, 43210
Contacts
Principal Investigator:
Ashley Cetnar, PhD
Ohio State University, Brain and Spine Hospital
Recruiting
Columbus, Ohio, United States, 43210
Contacts
Principal Investigator:
Ashley Cetnar, PhD
The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Recruiting
Columbus, Ohio, United States, 43210
Contacts
Principal Investigator:
Ashley Cetnar, PhD
Stefanie Spielman Comprehensive Breast Center
Recruiting
Columbus, Ohio, United States, 43212
Contacts
Principal Investigator:
Ashley Cetnar, PhD
Sponsor
Varian, a Siemens Healthineers Company
Last update posted
Mar 13, 2026
Last verified
Mar, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Varian, a Siemens Healthineers Company on 2026-03-13.